Skip to main content

Now I Trust My Heart to Lipitor OTC


The New York Times just published an excellent piece by Paula Span on a plan by Pfizer to make its cholesterol blockbuster drug Lipitor an over-the-counter (OTC) medication. A couple things caught my eye when reading this piece, not the least of which was the story was picked up by the Times after this tweet by our very own Ken Covinsky (FYI, in the twitterverse, Ken goes the name @geri_doc):
Pfizer wants to make Lipitor OTC. Just happens to be coming off patent. Message to FDA: no No NO NO! NO!! NO!!!

Well it looks like Ken’s excellent use of exclamation marks worked, as it did get attention. But what’s the big deal? It’s just Lipitor.

As Paula Span reports in the Times, a statin going over the counter is a big deal, both from a financial perspective for Pfizer, and from a patient safety perspective. Lipitor’s patent protection expires this November when at least one generic comes to the US market, so Pfizer is desperately looking for a way to continue milking this cash cow. One of their current ad campaigns shows just how nervous they are about patients switching to generics:
“If you're taking Lipitor for high cholesterol and it's working, why switch?”

Claritin is a great example of a drug company desire to fight for room in the over the counter shelf once patent protection was lost. Claritin was bringing in $3 billion prior to losing US patent protection in 2002. Schering-Plough protected some of those sales by launching an over-the-counter version of Claritin.  Last year, that over-the-counter version had $400 million in sales. Not as good as pre-patent protection, but still a nice chunk of change.

So, if Lipitor over-the-counter is a win for Pfizer, is it also a win for patients? Paula Span’s article does a much better job than I could ever do in clarifying both the pros and cons of making a drug like Lipitor over-the-counter, and I encourage you to read it and comment at the New Old Age website.

However, you may also just decide that the world has gone mad at even the notion of making something like Lipitor over the counter.  If that's the case, have no fear.  Both Seroquel and Zyprexa are coming off patent protection in 2012.

by: Eric Widera

Comments

Amy Corcoran said…
While I would love to see a statin over the counter in hopes that it would be less expensive to our older patients, I have concerns about all of the side effects. In the geripal world I am often dose reducing or discontinuing statins in those with life-limiting illness (which is still controversial). For example, a hospice patient with end-stage COPD or CHF may not have coverage for their statin medication - who should pay for it? Should the patient even be on the medication?
Sathish Kumar said…
I've been taking Lipitor pills for over 4 years-no side effects noted and my cholesterol is now 132, Trigycedrides 84, LDL 65, and HDL 50.

Popular posts from this blog

Practical Advice for the End of Life: A Podcast with BJ Miller

This week we talk with BJ Miller, hospice and palliative care physician, public speaker, and now author with Shoshana Berger of the book "A Beginner's Guide to the End."

As we note on the podcast, BJ is about as close as we get to a celebrity in Hospice and Palliative Care.  His TED Talk "What Really Matters at the End of Life" has been viewed more than 9 million times.  As we discuss on the Podcast, this has changed BJ's life, and he spends most of his working time engaged in public speaking, being the public "face" of the hospice and palliative care movement.

The book he and Berger wrote is filled to the brim with practical advice.  I mean, nuts and bolts practical advice.  Things like:
How to clean out not only your emotional house but your physical house (turns out there are services for that!)Posting about your illness on social media (should you post to Facebook)What is the difference between a funeral home and mortuaryCan I afford to die?  …

Improving Advance Care Planning for Latinos with Cancer: A Podcast with Fischer and Fink

In this week's GeriPal podcast we talk with Stacy Fischer, MD and Regina Fink, RN, PhD, both from the University of Colorado, about a lay health navigator intervention to improve advance care planning with Latinos with advanced cancer.  The issue of lay health navigators raises several issues that we discuss, including:
What is a lay health navigator?What do they do?  How are they trained?What do lay health navigators offer that specialized palliative care doesn't?  Are they replacing us?What makes the health navigator intervention particularly appropriate for Latinos and rural individuals?  For advance care planning? Eric and I had fun singing in French (yes French, not Spanish, listen to the podcast to learn why).
Enjoy! -@AlexSmithMD




You can also find us onYoutube!



Listen to GeriPal Podcasts on:
iTunes Google Play MusicSoundcloudStitcher

Transcript

Eric: Welcome to the GeriPal podcast. This is Eric Widera.

Alex: This is Alex Smith.

Eric: And Alex, I'm really excited about toda…

The Dangers of Fleet Enemas

The dangers of oral sodium phosphate preparations are fairly well known in the medical community. In 2006 the FDA issued it’s first warning that patients taking oral sodium phosphate preparations are at risk for potential for acute kidney injury. Two years later, over-the-counter preparations of these drugs were voluntarily withdrawn by the manufacturers.  Those agents still available by prescription were given black box warnings mainly due to acute phosphate nephropathy that can result in renal failure, especially in older adults. Despite all this talk of oral preparations, little was mentioned about a sodium phosphate preparation that is still available over-the-counter – the Fleet enema.

Why Oral Sodium Phosphate Preparations Are Dangerous 

Before we go into the risks of Fleet enemas, lets spend just a couple sentences on why oral sodium phosphate preparations carry significant risks. First, oral sodium phosphate preparations can cause significant fluid shifts within the colon …